Amelioration of Levodopa-induced Dyskinesias using Genetic Silencing of Striatal CaV1.3 in Parkinsonian Rats: Impact of Sex and Advancing Age
Objective: To advance understanding of striatal CaV1.3 (cacna1d) channel silencing as a therapeutic approach to reduce levodopa-induced dyskinesias (LID), a side effect of long-term escalating…Effect of the mGlu2/3 orthosteric agonist LY-404,039 on dyskinesia, psychosis-like behaviours, and parkinsonism in the MPTP-lesioned marmoset
Objective: To assess the effect of LY-404,039 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson’s disease (PD). Background:…A dose-response study of the effect of the mGlu2/3 orthosteric antagonist LY-341,495 on the anti-dyskinetic and anti-psychotic effect of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset
Objective: To assess the effects of different doses of the metabotropic glutamate 2 and 3 (mGlu2/3) orthosteric antagonist (OA) LY-341,495 on the anti-dyskinetic and anti-psychotic…Antidyskinetic Effects of CaV1.3 Calcium Channel Gene Silencing in Aged Male and Female Parkinsonian Macaques
Objective: To determine whether striatal CaV1.3 gene silencing ameliorates levodopa-induced dyskinesias (LID) in the preclinical gold-standard non-human primate (NHP) model without altering levodopa’s antiparkinsonian benefit.…Evaluation of the effect of adding a mGlu2/3 orthosteric antagonist to a highly selective 5-HT2A antagonist on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Objective: To determine whether the therapeutic effect of serotonin 2A (5-HT2A) receptor antagonism on dyskinesia and psychosis may be reversed by orthosteric antagonism of metabotropic…The mGlu2 positive allosteric modulator BINA extends enhances low dose L-DOPA anti-parkinsonian action in the MPTP-lesioned marmoset
Objective: To determine the effect of positive allosteric modulation of the metabotropic glutamate type 2 (mGlu2) receptor in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset using a low…Fingolimod-responsive complex hyperkinetic movement disorder in neuromyelitis optica spectrum disorder
Objective: Highlight a complex hyperkinetic movement disorder in Neuromyelitis optica spectrum disorder exacerbation with remission on fingolimod therapy. Background: Neuromyelitis optica spectrum disorder (NMOSD) can…Elimination of STN stimulation-induced dyskinesias with ViM DBS
Objective: To describe effects of thalamic deep brain stimulation (DBS) on severe dyskinesias induced by subthalamic nucleus (STN) DBS in a person with Parkinson’s disease…Cognitive and Motor aspects of a Brazilian population with Parkinson´s disease and Impulse Control Disorders and/or Related Behaviors – an observational study.
Objective: We analysed if Impulse Control Disorders (ICDs) and/or Related Behaviors (RBs) were associated with levodopa-induced dyskinesia (LIDs) in Brazilian patients with Parkinson´s disease (PD)…Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson’s disease
Objective: To investigate the potential of transcranial static magnetic field stimulation (tSMS) as a non-pharmacological, non-invasive, home-based treatment to manage levodopa-induced dyskinesias (LIDs) in Parkinson’s…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 44
- Next Page »